IceCure says West Cancer Center IRB clears ChoICE breast cancer cryoablation study
Reuters2026/08/20 12:12Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- IceCure won IRB clearance at West Cancer Center to start its ChoICE post-marketing study for ProSense breast cancer cryoablation.
- Enrollment is expected to begin in the coming weeks.
- ProSense holds FDA marketing authorization for local treatment of low-risk breast cancer with endocrine therapy in women aged 70+.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO30471) on August 20, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
ES Group holds extraordinary shareholder meeting in Alingsas
Reuters•2026/08/20 13:14
Maersk and Hapag-Lloyd Fairly Priced For Higher Rates -- Market Talk
Dow Jones•2026/08/20 13:13
Maris-Tech receives follow-on order from existing government intelligence customer
Reuters•2026/08/20 13:10
